Neumora Therapeutics is trading $0.56, up 11.62% versus the October 2 close of $0.50, after several steep declines over prior sessions. - No clear company-specific catalyst for October 5 was identified. - The investor-relations page lists its latest press release as August 14, 2026; major indices were essentially flat in the supplied pre-market snapshot, leaving a broader-market explanation unclear.